StrataXRT与美皮贴膜预防乳腺癌乳房切除术后急性放射性皮炎:患者内非劣效随机临床试验
这项多中心非劣效随机试验在4家澳大利亚医院于2017年1月1日至12月31日对44例乳房切除术后放疗的乳腺癌患者进行患者内随机分组,同一患者胸壁两半分别接受美皮贴膜与StrataXRT。符合方案分析的40例患者中,StrataXRT在主要结局时间加权平均急性放射性皮炎分级上劣于美皮贴膜,平均差0.19(95%CI 0.12-0.26;P<.001);次要结局显示两治疗非劣效,患者偏好接近。
要点
- StrataXRT在主要结局时间加权平均急性放射性皮炎分级上未达到非劣效界值,被认为劣于美皮贴膜。
- 胸壁两半的时间加权平均分级、最重急性放射性皮炎分级及湿性脱屑发生率等次要结局显示两治疗非劣效。
- 患者偏好接近:37.5%偏好StrataXRT,40%偏好美皮贴膜。
核心结论
- StrataXRT在主要结局未达到非劣效界值,被认为劣于美皮贴膜;但其易于涂抹和患者接受度提示,当美皮贴膜不实际可行时,仍可提供StrataXRT用于乳房切除术后放疗的急性放射性皮炎预防。
- 推荐与患者及照护者公开讨论,综合考虑疗效与实用性以确定最合适的皮肤保护剂。
研究设计与样本
- 多中心、非劣效随机临床试验,采用患者内随机分组,于2017年1月1日至12月31日在4家澳大利亚医院纳入44例经组织学确诊并接受乳房切除术后放疗的乳腺癌患者。
- 患者胸壁照射野的两半分别随机接受美皮贴膜(由护士粘贴,每1至2周或按需更换,确保放疗全程持续覆盖)与StrataXRT(患者每日自行涂抹于对侧半区,依从性记录于患者日记)。
- 主要结局为从放疗开始后10周内,各半区指定矩形内急性放射性皮炎时间加权平均分级平均差;符合方案分析40例。
主要发现
- 热释光剂量计测量显示内侧与外侧矩形之间剂量无显著差异。
- StrataXRT在主要结局劣于美皮贴膜,时间加权平均分级平均差0.19(95%CI 0.12-0.26;P<.001)。
- 次要结局——胸壁两半时间加权平均分级平均差、最重急性放射性皮炎分级及湿性脱屑发生率——显示两治疗非劣效。
- 患者偏好接近:37.5%偏好StrataXRT,40%偏好美皮贴膜。
- StrataXRT导致1例患者瘙痒,美皮贴膜导致3例瘙痒并致1例移除。
关键数值与推荐
- 主要结局非劣效性未达到:StrataXRT对比美皮贴膜的时间加权平均分级平均差为0.19(95%CI 0.12-0.26;P<.001)。
- 患者偏好:37.5%偏好StrataXRT,40%偏好美皮贴膜。
- 不良事件:StrataXRT组瘙痒1例,美皮贴膜组瘙痒3例并导致1例移除。
临床怎么用
- 作者认为,尽管StrataXRT在主要结局未达到非劣效界值且被认为劣于美皮贴膜,但其易于涂抹和患者接受度提示,当美皮贴膜不实际可行时,仍可提供StrataXRT用于乳房切除术后放疗的急性放射性皮炎预防。
- 作者推荐与患者及照护者公开讨论,综合考虑疗效与实用性以确定最合适的皮肤保护剂。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Acute radiation dermatitis (ARD) is a notable challenge for patients with breast cancer undergoing postmastectomy radiation therapy (RT). This study evaluates the efficacy, safety, and user experience of StrataXRT versus Mepitel Film for ARD prevention. METHODS AND MATERIALS: This multicenter, noninferiority trial involved intrapatient randomization of 44 patients with histologically confirmed breast carcinoma who had undergone postmastectomy RT across 4 Australian hospitals from January 1 to December 31, 2017. Patients were randomly assigned to receive Mepitel Film and StrataXRT on alternate halves of the irradiated chest wall. Mepitel Film was applied by nurses and replaced every 1 to 2 weeks or as necessary, ensuring continuous coverage throughout RT. Conversely, patients self-applied StrataXRT daily to the opposite half, with adherence details recorded in patient diaries. The primary outcome was the mean difference in the time-weighted average (TWA) grade of ARD within designated rectangles in each half over 10 weeks from the commencement of RT. RESULTS: Forty patients were analyzed per-protocol. Measurements using thermoluminescent dosimeters showed no significant dose differences between medial and lateral rectangles. StrataXRT was inferior to Mepitel Film in the primary outcome, with a mean difference in TWA grade of 0.19 (95% confidence interval, 0.12-0.26; P < .001). Secondary outcomes-mean difference in TWA grade in chest wall halves, worst ARD grade, and incidence of moist desquamation-showed noninferiority between treatments. Patient preferences were closely matched, with 37.5% favoring StrataXRT and 40% Mepitel Film. StrataXRT caused itching in 1 patient and Mepitel Film in 3, leading to 1 removal. CONCLUSIONS: Although StrataXRT did not meet the noninferiority threshold in the primary outcome and is considered inferior, its ease of application and patient acceptance suggest that it may still be offered for ARD prevention in postmastectomy RT when Mepitel Film is not a practical option. Open discussion with patients and caregivers is recommended to determine the most appropriate skin protection agent, considering both efficacy and practicality.
引用
- Lee SF, Yip PL, Spencer S, et al. StrataXRT and Mepitel Film for Preventing Postmastectomy Acute Radiation Dermatitis in Breast Cancer: An Intrapatient Noninferiority Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2024. PMID: 39608611. doi:10.1016/j.ijrobp.2024.11.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。